THE Generic and Biosimilar Medicines Association (GBMA) Board announced substantial changes today, coinciding with a crucial juncture in Australia's medicine policy landscape and the upcoming third Budget.
The board anticipates key concerns such as the cost of living, equitable access to medicines, and affordable healthcare to dominate the public discourse.
Expressing gratitude to the departing board members, GBMA's Independent Chair, Prof Jane Halton, acknowledged the invaluable contributions of Dennis Bastas, Chair and CEO of Arrotex Pharmaceuticals, and Juan Villar, Executive General Manager, North-East Asia-Pacific, Fresenius Kabi.
Highlighting their pivotal roles during critical industry negotiations, Halton commended their dedication.
Welcoming the incoming board members, both Halton and GBMA CEO, Marnie Peterson, conveyed confidence in the group's preparedness for the tough challenges ahead.
Among the newly appointed board members, Steve Graham, General Manager, Marketing at Arrotex, expressed his determination to uphold policies supporting the accelerated adoption of generics and biosimilars.
Similarly, Jim Margaritis, Teva Pharma's Vice President APAC and General Manager for Australia and New Zealand, and Selva Niroshan Selvaraja, General Manager ANZ at Accord Healthcare, shared their enthusiasm for contributing to enhancing healthcare accessibility and affordability.
Additionally, GBMA which represents 80% of the total generic volume on the PBS, strengthened its team with the appointment of Renee Richardson as Marketing and Policy Manager, signalling a strategic move to bolster the association's voice and support its growing membership base. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Mar 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Mar 24
